Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-001 pembrolizumab + lenvatinib versus chemotherapy in first-line advanced or recurrent endometrial carcinoma
2023-505614-17-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial in endometrial cancer (EC) comparing Keytruda + Lenvatinib with carboplatin + paclitaxel (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2023-505614-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505614-17-00.